The feasibility of combination therapy provides us with new targeted therapeutic options, such as combining anti-PD-1/PD-L1 or trastuzumab regimens for HER-2-positive GC patients with these specific therapeutic targets for liver metastasis, which might have promising results for the treatment. This evidence concerns the gene ERBB2 and gastric cancer.